T 0741/23 of 14.05.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T074123.20250514
- Date of decision
- 14 May 2025
- Case number
- T 0741/23
- Online on
- 29 April 2026
- Petition for review of
- -
- Application number
- 10176094.0
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Pharmaceutical combinations of an angiotensin receptor antagonist and a NEP inhibitor
- Applicant name
- Novartis Pharma AG
- Opponent name
- Generics [UK] Limited
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi
D Young & Co LLP
STADA Arzneimittel AG
Krka, d.d., Novo mesto
betapharm Arzneimittel GmbH
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Alfred E. Tiefenbacher (GmbH & Co. KG) - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 76(1)European Patent Convention Art 123(2)European Patent Convention Art 83European Patent Convention Art 56Rules of procedure of the Boards of Appeal Art 13(2)
- Keywords
- Divisional application - added subject-matter (no)
Amendments - correction of errors (yes)
Sufficiency of disclosure - (yes)
Inventive step - (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent as amended in the following version:
Claims 1 to 12 of the main request filed during oral proceedings on 14 May 2025 and the description and drawing of the patent specification.